Dr. David Louis is Benjamin Castleman Professor of Pathology and chair of Mass General Pathology. His clinical practice and research focuses on the molecular basis of brain tumors and the application of molecular diagnostics to their classification.
- Centers & Specialties
- Neuro-Oncology (Brain)
- Clinical Interests
- Autopsy Pathology
- Frozen Section Pathology
- Medical Education
- MD, SUNY at Stony Brook School of Medicine
- Residency, Albany Medical Center|Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Anatomic Pathology
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
David N. Louis, MD, is the Benjamin Castleman Professor of Pathology at HMS and Pathologist-in-Chief at MGH. Under Dr. Louis, the department has become a national leader in molecular diagnostics and pathology informatics, leading to a novel initiative in computational pathology. Dr. Louis' own neuropathology practice and research focuses on brain tumors, with an emphasis on the molecular basis of malignant gliomas and the application of molecular diagnostics to glioma classification. He has published nearly 300 original articles, as well as numerous reviews, chapters and books (h-index = 99). His laboratory was the first to demonstrate that molecular approaches could be used to classify malignant gliomas and that molecular approaches could be used to predict the response of malignant gliomas to specific therapies. Dr. Louis co-chaired and was the primary editor for the 2007 and the 2016 WHO Classification of Tumours of the Central Nervous System, is currently chairing the CNS tumor committee for the International Collaboration on Cancer Reporting, and is the founder and inaugural Steering Committee chair for cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy). He has served as chair of the Scientific Advisory Panel of the Brain Tumor Society, on the Board of Directors of the Society for Neuro-Oncology, and on editorial boards of more than 10 national and international journals. Dr. Louis was one of three editors for the 8th edition of Greenfield's Neuropathology and was first author of AFIP Fascicle on Non-neoplastic Disease of the Central Nervous System. He was co-chair of the NIH Brain Tumor Progress Review Group and founding chair of the Cancer Biomarkers Study Section at NIH.
2005 - Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma - JNEN (PDF)
Supplementary Information Table 1.xls
Supplementary Information Table 2.xls
Supplementary Information Table 3.xls
The 69th meeting of the MGH Scientific Advisory Committee (SAC), on April 6 and 7, focused on the hospital’s five thematic research centers.
Medical laboratory professionals week – an annual celebration of laboratory professionals and pathologists who play a vital role in every aspect of health care – runs from April 24-30.
Many ‘keen minds’ have worked toward a better understanding of disease to enable improved diagnosis and treatment.
55 Fruit Street
Boston, MA 02114-2696